Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol

Journal of Rheumatology

Volumn 28, Issue 10, 2001, Pages 2294-2297

  Yamamoto, T ^a   Moriwaki, Y ^a   Takahashi, S ^a   Tsutsumi, Z ^a   Hada, T ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

Allopurinol; Fenofibrate; Oxypurinol; Uric acid; Xanthine

Indexed keywords

ALLOPURINOL; FENOFIBRATE; HYPOXANTHINE; OXIPURINOL; PURINE DERIVATIVE; URIC ACID; XANTHINE;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EXCRETION; HUMAN; HUMAN EXPERIMENT; HYPOURICEMIA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; URINARY EXCRETION;

ADULT; ALLOPURINOL; ANTILIPEMIC AGENTS; CHOLESTEROL; CREATININE; DRUG INTERACTIONS; GOUT SUPPRESSANTS; HUMANS; HYPOXANTHINE; MALE; OXYPURINOL; PROCETOFEN; PURINES; TRIGLYCERIDES; URIC ACID; XANTHINE;

EID: 0034795608     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Potential use of fenofibrate and other fibric acid derivatives in the clinic
2. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in double-blind, placebo-control trials
3. Effect of micronized fenofibrate on plasma lipoprotein levels and hemostatic parameters of hypertriglyceridemic patients with low levels of high-density lipoprotein cholesterol in the fed and fasted state
4. Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state
5. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study
6. Plasma triglyceride and coronary heart diseases
7. Role of the peroxisome proliferator-activated receptor (PPAR) in mediating the effects of fibrates and fatty acids on gene expression
8. Uricosuric effect of fenofibrate in healthy volunteers
9. Effect of losartan potassium, an angiotensin II receptor antagonist, on renal excretion of oxypurinol and purine bases
10. Effect of glucose infusion on the renal transport of purine bases and oxypurinol
11. Effect of glucagon on renal excretion of oxypurinol and purine bases
12. Allopurinol kinetics and bioavailability: Intravenous, oral and rectal administration
13. Allopurinol kinetics
14. Metabolic studies of allopurinol, an inhibitor of xanthine oxidase
15. The renal excretion of oxypurines
16. Renal clearance of oxypurinol, the chief metabolite of allopurinol
17. Effect of furosemide on renal excretion of oxypurinol and purine bases
18. Indirect coupling of urate and p-aminohippurate transport to sodium in human brash-border membrane vesicles
19. Impaired lipoprotein metabolism in patients with primary gout - Influence of alcohol intake and body weight
20. Relation of serum uric acid to mortality and ischemic heart disease. The NHANES I Epidemiologic Follow-up Study
21. Uric acid as an independent risk factor in the treatment of hypertension
22. Serum uric acid and cardiovascular events in successfully treated hypertensive patients
23. Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hypemricemia
24. Hypertriglyceridemia and hyperuricemia: Effects of two fibric acid derivatives (bezafibrate and fenofibrate) in a double-blind, placebo-controlled trial
25. Harnsauresenkende wirkung einer kombination von benzbromaron und allopurinol - Untersuchungen unter standardiserten ernahrungsbedingungen